1390654-28-0

Basic information

• Product Name: 13-(2-fluorobenzyl)-9,10-dimethoxy-5H-[1,3]dioxolo[4,5-g]isoquinolino[3,2-a]isoquinoline-7-iumbromide
• Synonyms: 13-(2-fluorobenzyl)-9,10-dimethoxy-5H-[1,3]dioxolo[4,5-g]isoquinolino[3,2-a]isoquinoline-7-iumbromide
• CAS NO: 1390654-28-0
• Molecular Weight: 524.386
• Mol File: 1390654-28-0.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: 13-(2-fluorobenzyl)-9,10-dimethoxy-5H-[1,3]dioxolo[4,5-g]isoquinolino[3,2-a]isoquinoline-7-iumbromide(CAS DataBase Reference)
• NIST Chemistry Reference: 13-(2-fluorobenzyl)-9,10-dimethoxy-5H-[1,3]dioxolo[4,5-g]isoquinolino[3,2-a]isoquinoline-7-iumbromide(1390654-28-0)
• EPA Substance Registry System: 13-(2-fluorobenzyl)-9,10-dimethoxy-5H-[1,3]dioxolo[4,5-g]isoquinolino[3,2-a]isoquinoline-7-iumbromide(1390654-28-0)

Safety Data

• Hazardous Substances Data: 1390654-28-0(Hazardous Substances Data)

Usage

Molecular structure

13-(2-fluorobenzyl)-9,10-dimethoxy-5H-[1,3]dioxolo[4,5-g]isoquinolino[3,2-a]isoquinoline-7-ium bromide is a complex organic compound with a unique structure.

Functional groups

The compound contains a benzyl group with a fluorine atom (2-fluorobenzyl) and two methoxy groups (9,10-dimethoxy).

Ring system

It features a fused 5H-[1,3]dioxolo[4,5-g]isoquinolino[3,2-a]isoquinoline ring system.

Charged ion

The compound carries a positively charged quaternary ammonium ion.

Counterion

It has a bromide (Br-) counterion to balance the positive charge of the quaternary ammonium ion.

Potential applications

Due to its distinct structure and functional groups, this chemical may have potential applications in medicinal chemistry or pharmacology.

Upstream product

• 446-48-0 o-fluorobenzyl bromide 
• 39024-13-0 acetoneberberine 
• 633-65-8 berberine chloride 
• 483-15-8 7,8-dihydroberberine 

Downstream Products

• 1800465-47-7 13-(2-fluorobenzyl)-9,10-dimethoxy-5H-[1,3]dioxolo[4,5-g]isoquinolino[3,2-a]isoquinoline-8(6H)-one 

Relevant articles and documents

13-(2-methylbenzyl) berberine is a more potent inhibitor of MexXY-dependent aminoglycoside resistance than berberine

We previously showed that berberine attenuates MexXY efflux-dependent aminoglycoside resistance in Pseudomonas aeruginosa. Here, we aimed to synthesize berberine derivatives with higher MexXY inhibitory activities. We synthesized 11 berberine derivatives, of which 13-(2-methylbenzyl) berberine (13-o-MBB) but not its regiomers showed the most promising MexXY inhibitory activity. 13-o-MBB reduced the minimum inhibitory concentrations (MICs) of various aminoglycosides 4- to 128 fold for a highly multidrug resistant P. aeruginosa strain. Moreover, 13-o-MBB significantly reduced the MICs of gentamicin and amikacin in Achromobacter xylosoxidans and Burkholderia cepacia. The fractional inhibitory concentration indices indicated that 13-o-MBB acted synergistically with aminoglycosides in only MexXY-positive P. aeruginosa strains. Time-kill curves showed that 13-o-MBB or higher concentrations of berberine increased the bactericidal activity of gentamicin by inhibiting MexXY in P. aeruginosa. Our findings indicate that 13-o-MBB inhibits MexXY-dependent aminoglycoside drug resistance more strongly than berberine and that 13-o-MBB is a useful inhibitor of aminoglycoside drug resistance due to MexXY.

Novel 8-oxoprotoberberine derivatives or pharmaceutically acceptable salts thereof, preparation method thereof and pharmaceutical composition for prevention or treatment of diseases induced by activation of NFAT5 containing the same as an active ingredient

The present invention relates to: novel 8-oxoprotoberberine derivatives or pharmaceutically acceptable salts thereof; a method for preparing same; and a pharmaceutical composition containing the same as active ingredient for preventing or treating diseases related to NFAT5 activity. According to the present invention, the novel 8-oxoprotoberberine derivatives or the pharmaceutically acceptable salts thereof is proven to: have an oral absorption rate which is significantly higher thatn than of the prior protoberberine; inhibit NFAT5 activity and secretion of inflammatory cyotokine by directly inhibiting transcription of NFAT5; and reduce expression of NFAT5 in a mouse with rheumarthritis. Therefore, the novel 8-oxoprotoberberine derivatives or the pharmaceutically acceptable salts thereof can be advantageously used as a pharmaceutical composition for preventing or treating NFTA5 activity-related diseases, particularly rheumarthritis or inflammation disease.(AA) Days after immune response induction(BB) Control group(CC) Example 1COPYRIGHT KIPO 2015